Latest News
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
30 January 2026 - Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) said on Friday that it has entered into a strategic collaboration with CSPC Pharmaceuticals to advance eight programmes targeting obesity and type 2 diabetes...
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
30 January 2026 - Biotechnology company Ascletis Pharma Inc (HKEX:1672) on Thursday reported positive topline results from the Phase III open-label study of denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FA...
Repertoire Immune Medicines teams up with Eli Lilly and Company to develop tolerizing therapies for autoimmune diseases
30 January 2026 - Biotechnology company Repertoire Immune Medicines announced on Thursday that it has entered into a strategic collaboration with pharmaceutical company Eli Lilly and Company (NYSE:LLY) to develop tolerizing therapies for multiple aut...
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
30 January 2026 - German clinical-stage biotech company Innovative Molecules GmbH announced on Thursday announced the successful completion of its Phase 1 clinical development programme and the transition into Phase 2 for its oral selective helicase ...
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
30 January 2026 - Clinical-stage biopharmaceutical company MicuRx Pharmaceuticals Inc announced on Thursday that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for MRX-5, a novel oral antibacteria...